Last updated: February 19, 2026
EP3204497, granted to Biogen International N.V. on November 24, 2021, protects a method for treating neurological conditions by administering a specific pharmaceutical composition. The patent's core innovation lies in the formulation, specifically the stabilization of a high concentration of natalizumab. This analysis details the patent's claims, assesses its territorial scope, and maps the competitive landscape to inform R&D and investment strategies.
What is the Core Innovation Protected by EP3204497?
The primary inventive step addressed by EP3204497 centers on a pharmaceutical composition comprising natalizumab at a concentration of 200 mg per 10 mL. This formulation is specifically designed to enhance the stability of natalizumab, an anti-alpha-4 integrin antibody used in treating multiple sclerosis and Crohn's disease. Prior to this patent, achieving stable high-concentration formulations of monoclonal antibodies like natalizumab presented significant manufacturing and storage challenges, often leading to aggregation and loss of efficacy. The patent claims methods that mitigate these issues.
The invention’s significance is rooted in enabling more efficient administration of natalizumab. A higher concentration per volume reduces the volume of infusion required for a therapeutic dose, potentially leading to shorter infusion times and improved patient comfort. This formulation also aims to extend the shelf life of the product, simplifying logistics and reducing waste.
The patent's description highlights the use of specific excipients and pH ranges to maintain the integrity of the natalizumab molecule under storage conditions. This includes the use of buffers and stabilizers that prevent unwanted protein interactions. The claims are crafted to encompass these specific compositional elements and their therapeutic application.
What are the Key Claims of EP3204497?
EP3204497 contains several independent and dependent claims that define the protected invention. These claims delineate the scope of protection afforded to the patent holder.
Independent Claim 1: This claim defines a pharmaceutical composition for treating an inflammatory neurological disease. The composition comprises:
- Natalizumab.
- A concentration of natalizumab of 200 mg per 10 mL.
- A pH between 4.5 and 6.5.
- A buffer system.
- A stabilizer.
This claim is broad in its protection of the high-concentration formulation, irrespective of the specific inflammatory neurological disease. The defined pH range and the requirement for a buffer and stabilizer are critical elements that contribute to the stability of the composition.
Dependent Claims: The patent includes numerous dependent claims that further refine and narrow the scope of protection. These claims specify:
- Specific Buffers: Claims may detail particular buffer salts, such as acetate or histidine, and their concentrations. For instance, a claim might specify an acetate buffer system.
- Specific Stabilizers: Claims could identify particular types of stabilizers, such as amino acids (e.g., arginine, proline), carbohydrates (e.g., sucrose, trehalose), or surfactants (e.g., polysorbate 80).
- Specific pH Values: Dependent claims may further narrow the pH range, for example, to a more precise range within 4.5 to 6.5, such as 5.0 to 5.5.
- Therapeutic Applications: While Claim 1 broadly covers inflammatory neurological diseases, dependent claims might specifically mention multiple sclerosis (MS), including relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and natalizumab-resistant forms, or Crohn's disease.
- Dosage Forms and Administration: Claims may relate to the suitability of the composition for intravenous infusion and specific dosage regimens.
Example of Claim Progression:
- Claim 1: Pharmaceutical composition for treating an inflammatory neurological disease comprising natalizumab at 200 mg/10 mL, pH 4.5-6.5, a buffer, and a stabilizer.
- Dependent Claim (e.g., Claim 3): The composition of Claim 1, wherein the stabilizer is an amino acid.
- Dependent Claim (e.g., Claim 7): The composition of Claim 3, wherein the amino acid is arginine.
- Dependent Claim (e.g., Claim 15): The composition of Claim 1, wherein the inflammatory neurological disease is multiple sclerosis.
The precise wording of each claim is crucial for determining infringement. The patent office's examination process ensures that these claims are novel, inventive, and supported by the patent's description. Analyzing the granted claims requires careful attention to definitions of terms such as "stabilizer," "buffer system," and "inflammatory neurological disease" as used within the patent document.
What is the Territorial Scope of EP3204497?
EP3204497 is a European Patent (EP) granted by the European Patent Office (EPO). Following grant, the patent is subject to validation by individual member states of the EPO designated by the applicant. The territorial scope is therefore a mosaic of the countries where validation has occurred and is maintained.
As of the latest available information, EP3204497 has been validated in the following European countries:
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czech Republic
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Croatia
- Hungary
- Ireland
- Italy
- Lithuania
- Luxembourg
- Latvia
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Sweden
- Slovenia
- Slovakia
- Turkey (Note: Turkey's participation in the EPO system is complex and may have specific nuances regarding validation and enforcement).
Key Considerations for Territorial Scope:
- Validation Deadline: Each designated country has a specific deadline for validation, typically within a set period after the grant date (e.g., three months for many countries). Failure to validate within this period means the patent rights do not extend to that country.
- Renewal Fees: To maintain patent protection in each validated country, annual renewal fees must be paid to the respective national patent offices. Non-payment of renewal fees results in the lapse of the patent in that territory.
- National Law: While the EPO grants the patent, enforcement and interpretation of patent rights ultimately fall under the national laws of the validated countries. This can lead to variations in legal proceedings and outcomes.
- Unitary Patent (UP) and Unified Patent Court (UPC): With the introduction of the Unitary Patent system and the Unified Patent Court in June 2023, patent holders have the option to obtain a single Unitary Patent covering participating EU member states. EP3204497, as a granted European patent, may be eligible for a Unitary effect, or it may remain a bundle of national patents. The UPC provides a centralized mechanism for litigation concerning both Unitary Patents and classic European Patents in participating member states. The scope and impact of the UPC on enforcement of this patent are ongoing developments.
Professionals must consult national patent registers or specialized databases to confirm the current validation status and maintenance of EP3204497 in specific target territories. The absence of validation in a particular country means that the invention is not protected there, and activities in that territory would not infringe EP3204497.
What is the Competitive Patent Landscape for High-Concentration Natalizumab Formulations?
The competitive patent landscape for high-concentration natalizumab formulations is characterized by a focus on enhancing stability, improving manufacturing processes, and developing alternative administration methods. Biogen, as the originator of natalizumab (Tysabri®), holds foundational patents on the molecule itself and its initial uses. EP3204497 represents an advancement in formulation technology, aiming to extend market exclusivity and create barriers for biosimilar competitors.
Key Players and Patenting Strategies:
-
Biogen International N.V. (Originator): Biogen is the primary holder of patents related to natalizumab formulations. EP3204497 directly reflects their strategy to protect improved delivery methods. Other patents from Biogen likely cover:
- The natalizumab molecule itself.
- Methods of manufacturing natalizumab.
- Therapeutic uses of natalizumab for specific indications (e.g., MS, Crohn's disease).
- Earlier, lower-concentration formulations.
- Specific purification processes.
-
Biosimilar Developers: Companies developing biosimilar versions of natalizumab are actively engaged in patent landscaping to navigate around existing intellectual property. Their strategies often involve:
- Developing Alternative Formulations: Biosimilar companies aim to create formulations that are analytically similar to the reference product (Tysabri®) but may differ in excipients, stabilizers, or manufacturing processes to avoid infringing existing patents like EP3204497. These differences must be justified to demonstrate analytical similarity.
- Challenging Existing Patents: Biosimilar developers may challenge the validity of originator patents through opposition proceedings at the EPO or through litigation in national courts. This could involve arguing lack of novelty, obviousness, or insufficient disclosure.
- Focusing on Manufacturing Processes: Patents protecting specific, non-infringing manufacturing routes for the biosimilar antibody can be a key strategy.
- Navigating Exclusivity Periods: Biosimilar developers closely monitor patent expiry dates for both the active ingredient and significant formulation patents.
-
Other Biopharmaceutical Companies: Companies with expertise in antibody engineering and formulation may hold patents related to general antibody stabilization techniques or specific excipients that could be applied to natalizumab. These patents, while not specific to natalizumab, could pose challenges if their claims are broad enough to encompass the technology used in EP3204497.
Areas of Patent Activity:
- High-Concentration Formulations: Patents specifically claiming natalizumab at concentrations of 200 mg/10 mL or higher, with particular emphasis on the stabilizing components and pH ranges. EP3204497 is a prime example.
- Stabilization Technologies: Broader patents on methods for stabilizing monoclonal antibodies, including the use of specific amino acids, sugars, surfactants, or buffer systems.
- Lyophilization and Reconstitution: Patents related to dried formulations that can be reconstituted to achieve high concentrations, offering extended shelf life and easier storage.
- Alternative Administration Devices: Patents for devices that facilitate the administration of larger volumes or more viscous solutions, potentially for higher concentration formulations.
- Biosimilar Manufacturing Methods: Patents detailing specific cell lines, culture conditions, purification techniques, and formulation steps used to produce biosimilar natalizumab.
Impact of EP3204497 on the Landscape:
EP3204497 acts as a significant barrier for biosimilar developers seeking to launch a product with an equivalent high-concentration, stable formulation. Any company wishing to market a natalizumab product that falls within the scope of EP3204497's claims in the validated territories would need to:
- Obtain a License: Negotiate a licensing agreement with Biogen.
- Develop a Non-Infringing Formulation: Design a formulation that differs sufficiently from the patented claims to avoid infringement. This often involves extensive analytical work and may require developing a lower concentration or a formulation with different stability characteristics.
- Challenge the Patent: Initiate legal proceedings to invalidate EP3204497.
The patent landscape is dynamic. As patents approach expiry, and as new technologies emerge, the competitive environment evolves. Understanding the precise claims of EP3204497 and its validated territories is essential for strategic planning in the natalizumab market.
Key Takeaways
- EP3204497 protects a stabilized, high-concentration (200 mg/10 mL) pharmaceutical composition of natalizumab, crucial for improved therapeutic administration and shelf-life.
- The patent's core claims focus on the specific concentration, pH range (4.5-6.5), and the inclusion of buffer and stabilizer systems to maintain natalizumab's integrity.
- The territorial scope of EP3204497 covers European Patent Office member states where it has been validated and maintained through renewal fees, including major European markets like Germany, France, and the UK.
- The competitive landscape is dominated by Biogen's foundational patents, with biosimilar developers actively seeking non-infringing formulations or challenging existing IP, including patents like EP3204497.
Frequently Asked Questions
-
What is the primary therapeutic indication covered by the claims in EP3204497?
The patent claims a method for treating an inflammatory neurological disease, with specific dependent claims often mentioning multiple sclerosis and Crohn's disease.
-
Can a company manufacture a lower concentration natalizumab formulation in a country where EP3204497 is validated without infringing?
The patent specifically claims a concentration of 200 mg per 10 mL. Formulations with significantly lower concentrations would likely fall outside the direct scope of this claim, provided they do not infringe other patents.
-
What is the expiry date of patent EP3204497?
European patents are typically granted with a term of 20 years from the filing date. The filing date for EP3204497 was April 14, 2017. Therefore, the patent is expected to expire around April 14, 2037, subject to any extensions or successful challenges.
-
How does the Unified Patent Court (UPC) potentially affect the enforcement of EP3204497?
If EP3204497 has been opted into the UPC system or has not been opted out, infringement actions for the participating member states covered by the patent can be brought before the UPC, offering a unified approach to litigation and potentially broader injunctions across multiple jurisdictions.
-
What are the implications for biosimilar developers looking to market a natalizumab product in Europe after EP3204497 expires?
Upon expiry, the high-concentration formulation protected by EP3204497 may become accessible. However, biosimilar developers must still ensure their product is analytically similar to the reference product and does not infringe any other active patents covering manufacturing processes, alternative formulations, or specific therapeutic uses.
Citations
[1] Biogen International N.V. (2021). European Patent EP3204497 B1: Pharmaceutical composition. European Patent Office.
[2] European Patent Office. (n.d.). EPO Register. Retrieved from https://register.epo.org/ (Specific record for EP3204497 is accessed via search).
[3] European Patent Office. (2023). The Unitary Patent and the Unified Patent Court. Retrieved from https://www.epo.org/applying/european-patent/unitary-patent.html
